CTRI/2021/03/032023已完成不适用
Evaluation of Skin Safety of 3 topical formulations (Minoxidil 2%) for Primary Skin Irritation Using Skin Irritation Test (Patch Test in Humans)IS 4011:2018 Guidelines.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Evaluation of skin irritation reactions using Draize scale
研究概览
简要总结
The test products,
- MinoxidilTopical Solution USP 2% (Sun Pharma) - B No.: 26202491SB006
- MinopepEva 2% Topical Solution - B No.: C20B018
- Mintop2% Topical Solution - B No.: CT10016
were dermatologically tested and found to be “Non-Irritant†based on IS 4011:2018, Methods of Test for safety evaluation ofcosmetics - Third Revision.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Having apparently healthy skin on test area.
- •Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the trial.
排除标准
- •Pregnancy (by history) and lactating women.
- •Scars, excessive terminal hair or tattoo on the studied area Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
结局指标
主要结局
Evaluation of skin irritation reactions using Draize scale
时间窗: 48 Hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
To evaluate safety of a test product for skin irritatioCTRI/2022/06/043046Cipla Ltd52
已完成
不适用
To test the safety of a test product in healthy human volunteers.CTRI/2022/01/039409CIPLA LTD52
已完成
不适用
To test the safety of 3 test products for skin irritatioCTRI/2020/08/027431Sun Pharmaceutical Industries Ltd56
已完成
不适用
To test the safety of 3 test products for skin irritatioCTRI/2021/03/032023Sun Pharmaceutical Industries Ltd56
已完成
不适用
To evaluate safety of 3c test products for skin irritation.CTRI/2021/08/035395Sun Pharmaceutical Industries Ltd53